Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, Inc., and Prometheus Laboratories Inc.

Community Practice Connections®: Medical Crossfire®: Crossroads in Advanced RCC Decision- Making: With Many Options, How Will You Treat Your Patient Today?... And Tomorrow?


Release Date: March 29, 2019
Expiration Date: March 29, 2020
Media: Internet - based

Activity Overview

Community Practice Connections®: Medical Crossfire®: Crossroads in Advanced RCC Decision-Making: With Many Options, How Will You Treat Your Patient Today?... And Tomorrow? is a case-based, interactive, online CME activity based on a live symposium that was held adjunct to the 2019 Genitourinary Cancers Symposium in San Francisco. Clinical decision-making in the setting of metastatic renal cell carcinoma (mRCC) has been undergoing dramatic change. The approval of new systemic agents has expanded the lines of therapy available to patients, and raised questions about how rational treatment planning and effective sequencing of new and older standards of care can optimize patient outcomes. Additionally, the benefit of real-world experience and data from subgroup analyses and long-term follow-up of landmark clinical trials continue to refine treatment strategies in RCC.

This program consists of a series of interactive clinical vignettes and short video interviews with leading experts in renal cell carcinoma (RCC). The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, Inc., and Prometheus Laboratories Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/Ce certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, and urologists involved in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with RCC are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the biologic factors that drive renal cell carcinoma (RCC) and provide the rationale for using targeted agents and immunotherapies as single agents and in combination
  • Evaluate practice-changing and emerging data from RCC clinical trials across the advanced disease continuum
  • Apply best practices to proactively identify and mitigate treatment-related toxicities related to therapy for metastatic RCC
  • Integrate knowledge of patient characteristics, as well as the efficacy and safety of single-agent and combination systemic therapies, into clinical decision-making for patients with metastatic RCC

Faculty, Staff, and Planners’ Disclosures

Laurence Albiges, MD, PhD
Head, Genitourinary Oncology Unit
Department of Cancer Medicine
Gustave Roussy Institute
Villejuif, France
 

Disclosures: Consultant: Novartis, AMGEN, BMS, Ipsen, Roche, Pfizer, Astellas, Merck.

Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: AstraZeneca, Alexion, Bayer, Bristol-Myers Squibb/ER Squibb and Sons LLC, Cerulean, Eisai, Foundation Medicine, Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, Takeda; Consultant: AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers Squibb/ER Squibb and Sons LLC, Cerulean, Eisai, Foundation Medicine, Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Lilly, Ipsen, Up-to-Date, NCCN, Analysis Group; Other: Honoraria: AstraZeneca, Alexion, Sanofi-Aventis, Bayer, Bristol-Myers Squibb/ER Squibb and Sons LLC, Cerulean, Eisai, Foundation Medicine, Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, NEJM, Lancet Oncology, Heron Therapeutics, Lilly.

Sumanta K. Pal, MD
Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, CA

Disclosures: Consultant: Pfizer, BMS, Exelixis, Novartis, Ipsen, GSK, Astellas, Medivation; Speakers Bureau: Genentech.

Thomas Powles, MBBS, MRCP, MD
Clinical Professor of Genitourinary Oncology (HCC) Experimental Cancer Medicine Centre
Barts Cancer Institute
Barts and The London School of Medicine and Dentistry
London, United Kingdom
 

Disclosures: Grant/Research Support: MSD, AstraZeneca, Roche; Other: Honoraria: BMS, Merck, Roche, AstraZeneca, Novartis, Pfizer, Ipsen, MSD.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI. Additionally, PER® is required by the ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
282930
Filter By